885693-48-1

Basic information

• Product Name: 5-AMINO-1-BOC-3',4',5',6'-TETRAHYDRO-2'H-[2,4']BIPYRIDINYL
• Synonyms: 5-AMINO-1-BOC-3',4',5',6'-TETRAHYDRO-2'H-[2,4']BIPYRIDINYL;5-Amino-3',4',5',6'-tetrahydro-2'H-[2,4']bipyridinyl-1'-carboxylic acid tert-butyl ester;tert-butyl 4-(5-aminopyridin-2-yl)piperidine-1-carboxylate
• CAS NO: 885693-48-1
• Molecular Formula: C₁₅H₂₃N₃O₂
• Molecular Weight: 277.36
• Mol File: 885693-48-1.mol

Chemical Properties

• Boiling Point: 407.6°C at 760 mmHg
• Flash Point: 200.3°C
• Appearance: /
• Density: 1.113g/cm³
• Vapor Pressure: 7.44E-07mmHg at 25°C
• Refractive Index: 1.539
• Storage Temp.: 2-8°C
• PKA: 6.36±0.29(Predicted)
• CAS DataBase Reference: 5-AMINO-1-BOC-3',4',5',6'-TETRAHYDRO-2'H-[2,4']BIPYRIDINYL(CAS DataBase Reference)
• NIST Chemistry Reference: 5-AMINO-1-BOC-3',4',5',6'-TETRAHYDRO-2'H-[2,4']BIPYRIDINYL(885693-48-1)
• EPA Substance Registry System: 5-AMINO-1-BOC-3',4',5',6'-TETRAHYDRO-2'H-[2,4']BIPYRIDINYL(885693-48-1)

Safety Data

• Hazardous Substances Data: 885693-48-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-AMINO-1-BOC-3',4',5',6'-TETRAHYDRO-2'H-[2,4']BIPYRIDINYL is used as a key intermediate in the synthesis of various drugs for the treatment of central nervous system disorders and psychiatric conditions. Its presence in the molecular structure of these drugs aids in modulating their therapeutic effects and enhancing their efficacy.
Used in Organic Synthesis:
In the field of organic synthesis, 5-AMINO-1-BOC-3',4',5',6'-TETRAHYDRO-2'H-[2,4']BIPYRIDINYL is utilized as a versatile building block for the creation of a wide range of organic compounds. Its unique structure and functional groups make it a valuable component in the development of new chemical entities with potential applications in various industries.
Used in Drug Development:
5-AMINO-1-BOC-3',4',5',6'-TETRAHYDRO-2'H-[2,4']BIPYRIDINYL is employed as a crucial component in the development of new therapeutic treatments. Its incorporation into drug molecules allows for the exploration of novel mechanisms of action and the potential discovery of more effective and safer medications for various diseases and conditions.

InChI:InChI=1/C15H25N3O2/c1-15(2,3)20-14(19)18-10-12(16)4-5-13(18)11-6-8-17-9-7-11/h4-5,11,17H,6-10,16H2,1-3H3

Upstream product

• 4487-59-6 2-bromo-5-nitropyridine 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 1085841-76-4 C₁₅H₂₁N₃O₄ 
• 885693-47-0 tert-butyl 5-nitro-5’,6’-dihydro-[2,4‘-bipyridine]-1‘(2’H)-carboxylate 

Downstream Products

• 1089654-02-3 1,1-dimethylethyl 4-[5-({5-methyl-4-[(2-{[(1-methylethyl)amino]carbonyl}phenyl)amino]-2-pyrimidinyl}amino)-2-pyridinyl]-1-piperidinecarboxylate 
• 1085836-61-8 2-phenyl-5-trifluoromethyloxazole-4-carboxylic acid (1'-cyclopropanecarbonyl-1',2',3',4',5',6'-hexahydro[2,4']bipyridinyl-5-yl)amide 
• 1085838-00-1 4-{5-[(2-phenyl-5-trifluoromethyl-1,3-oxazole-4-carbonyl)amino]pyridin-2-yl}piperidine-1-carboxylic acid methyl ester 
• 1085835-97-7 4-{5-[(2-phenyl-5-trifluoromethyloxazole-4-carbonyl)amino]-3',4',5',6'-tetrahydro-2'H-(2,4'-bipyridinyl)-1'-carbonyl}-trans-cyclohexanecarboxylic acid 
• 1085841-79-7 2-phenyl-5-trifluoromethyloxazole-4-carboxylic acid (1',2',3',4',5',6'-hexahydro-(2,4'-bipyridin-5-yl)amide) 
• 1085843-37-3 5-[(2-phenyl-5-trifluoromethyloxazole-4-carbonyl)amino]-3',4',5',6'-tetrahydro-2'H-(2,4'-bipyridinyl)-1'-carboxylic acid tert-butyl ester 
• 1566584-44-8 tert-butyl 4-(5-((4-((2-(2-methoxy-2-oxoethyl)phenyl)ethynyl)-5-methylpyrimidin-2-yl)amino)pyridin-2-yl)piperidine-1-carboxylate 
• 1566583-84-3 2-(2-(2-(5-methyl-2-((6-(1-methylpiperidin-4-yl)pyridin-3-yl)amino)pyrimidin-4-yl)ethyl)phenyl)acetamide 
• 1566583-83-2 2-(2-(2-(5-methyl-2-((6-(piperidin-4-yl)pyridin-3-yl)amino)pyrimidin-4-yl)ethyl)phenyl)acetamide 
• 1566584-47-1 tert-butyl 4-(5-((4-(2-(2-amino-2-oxoethyl)phenethyl)-5-methylpyrimidin-2-yl)amino)pyridin-2-yl)piperidine-1-carboxylate 
• 1566584-46-0 2-(2-(2-(2-((6-(1-(tert-butoxycarbonyl)piperidin-4-yl)pyridin-3-yl)amino)-5-methylpyrimidin-4-yl)ethyl)phenyl)acetic acid 
• 1566584-45-9 tert-butyl 4-(5-((4-(2-(2-methoxy-2-oxoethyl)phenethyl)-5-methylpyrimidin-2-yl)amino)pyridin-2-yl)piperidine-1-carboxylate 
• 1566583-96-7 2-(2-(2-(2-((6-(1-methylpiperidin-4-yl)pyridin-3-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)phenyl)acetamide 
• 1566583-95-6 2-(2-(2-(2-((6-(piperidine-4-yl)pyridin-3-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)phenyl)acetamide 

Relevant articles and documents

VEGFR3 INHIBITORS

This invention relates to a compound of the formula (I): The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for th

VEGFR3 INHIBITORS

This invention relates to compounds of the formula (I). The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphanglogenesis.

Discovery of orally active carboxylic acid derivatives of 2-phenyl-5-trifluoromethyloxazole-4-carboxamide as potent diacylglycerol acyltransferase-1 inhibitors for the potential treatment of obesity and diabetes

Diacylglycerol acyltransferase-1 (DGAT-1) is the enzyme that catalyzes the final and committed step of triglyceride formation, namely, the acylation of diacylglycerol with acyl coenzyme A. DGAT-1 deficient mice demonstrate resistance to weight gain on hig

DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS

Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

ANTHRANILAMIDES

The present invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, and Het are as defined herein. Compounds of the present invention are useful as Aurora kinase inhibitors.

METHOD OF INHIBITING C-KIT KINASE

A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.

METHOD OF INHIBITING FLT3 KINASE

A method of reducing or inhibiting kinase activity of FLT3 in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 using a compound of the present invention (I), or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.

INHIBITORS OF C-FMS KINASE

The invention is directed to compounds of Formula (I): wherein A, X, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula (I), are also provided.

SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR

The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from compounds of Formula I′: Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.